

bsm-54138R**[Primary Antibody]****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

JAK1 Recombinant Rabbit mAb**— DATASHEET —**

Host: Rabbit	Isotype: IgG	Applications: WB (1:500-1000) Flow-Cyt (1:50-100) Reactivity: Human, Mouse, Rat Predicted MW.: 133 kDa Observed MW.: 130-135 kDa Subcellular Location: Cytoplasm
Clonality: Recombinant	CloneNo.: 2B12	
GeneID: 3716	SWISS: P23458	
Target: JAK1		
Immunogen: A synthesized peptide derived from human JAK1: 625-660.		
Purification: affinity purified by Protein A		
Concentration: 1mg/ml		
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: Janus kinase 1 (JAK1) is a member of a new class of non-receptor protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The second phosphotransferase domain bears all the hallmarks of a protein kinase, although its structure differs significantly from that of the PTK and threonine/serine kinase family members. JAK1 is a large, widely expressed membrane-associated phosphoprotein. It is involved in the interferon-alpha/beta and -gamma signal transduction pathways. The reciprocal interdependence between JAK1 and TYK2 activities in the interferon-alpha pathway, and between JAK1 and JAK2 in the interferon-gamma pathway, may reflect a requirement for these kinases in the correct assembly of interferon receptor complexes. These kinases couple cytokine ligand binding to tyrosine phosphorylation of various known signaling proteins and a unique family of transcription factors termed the signal transducers and activators of transcription, or STATs.		

— VALIDATION IMAGES —

25 ug total protein per lane of various lysates (see on figure) probed with JAK1 monoclonal antibody, unconjugated (bsm-54138R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



The A431 (H) cells were fixed with 4% PFA (10 min at r.t.) and then permeabilized with 90% ice-cold methanol for 20 min at -20°C, the cells then were incubated in 5% BSA to block non-specific protein-protein interactions (30 min at r.t.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green): Rabbit Anti-JAK1 antibody (bsm-54138R, 1:100); Isotype Control (orange): Rabbit IgG (bs-0295P). Blank control (black): PBS. Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=17.4]** Hui Yan. et al. Elaboration a ROS-responsive darutigenol prodrug nanoassemblies for inflammatory arthritis

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

- treatment. NANO TODAY. 2024 Apr;55:102220 WB ;Mouse. 10.1016/j.nantod.2024.102220
- **[IF=8.3]** Menghan Liu. et al. Pinellia exosomal vesicles remodulate tumor-associated macrophage polarization via the serine synthesis/JAK/STAT signaling pathway to inhibit lung cancer growth. PHYTOMEDICINE. 2026 Jan;;157759 WB ;Human. 41539095
 - **[IF=8.3]** Yifan Zhang. et al. Yuzhi Zhixue Granules regulate the JAK/STAT pathway to affect T-cell differentiation in the colon of ulcerative colitis. PHYTOMEDICINE. 2025 Aug;;157198 WB ;Mouse. 40907405
 - **[IF=8.3]** Qiao Xu. et al. Biological activity study of a pine pollen extract rich in dihydroquercetin for the treatment of psoriasis. PHYTOMEDICINE. 2025 Nov;;157597 WB ;Mouse. 10.1016/j.phymed.2025.157597
 - **[IF=7.5]** Junchao Wu. et al. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis. BIOMED PHARMACOTHER. 2024 Feb;171:116167 WB,IHC ;Mouse. 38262152